NP137: Clinical Trials

5 trials of NP137, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Active not recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1
Phase 22Active not recruiting 1, Terminated 1

Follow NP137: new trials by email Literature Review of NP137 trials Research Report on NP137

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
NP137 - Pancreatic Cancer
Phase 1Not yet recruitingAram Hezel252026-09-012026-02-05
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory
Phase 1 / Phase 2TerminatedCentre Leon Berard12024-09-112025-02-20
Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma
NP137, Oxaliplatin, Irinotecan - Pancreatic Ductal Adenocarcinoma
Phase 1CompletedUniversity Hospital, Grenoble432023-03-282026-05-19
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
NP137, Atezolizumab, Bevacizumab - Hepatocellular Carcinoma
Phase 1Active not recruitingUniversity Hospital, Grenoble432023-03-152026-05-20
GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab
NP137, Pembrolizumab, Paclitaxel - Endometrial Carcinoma, Cervix Carcinoma
Phase 1 / Phase 2Active not recruitingNETRIS Pharma2402020-12-142026-11-16

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Endometrial Neoplasms (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Pancreatic Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

University Hospital, Grenoble (2)  ·  Aram Hezel (1)  ·  Centre Leon Berard (1)  ·  NETRIS Pharma (1)

Countries

France (4)  ·  United States (1)

Top investigators

Aram Hezel (1)

Results publications

PMID 42020751